Sökning: "Physiologically-Based Pharmacokinetics"
Visar resultat 1 - 5 av 6 avhandlingar innehållade orden Physiologically-Based Pharmacokinetics.
1. Mechanistic Based Pharmacokinetic-Pharmacodynamics models for Drug Interactions and Disease Population Predictions
Sammanfattning : Therapeutic dose of a medication refers to the quantity of a drug required to produce a pharmacological effect without causing unacceptable adverse events. Dose selection in the clinical setting is not straight forward due to various factors, including specific patient factors such as age, sex, weight, genetic variants and renal/hepatic function, as well as external factors such as food and co-medication, all of which can influence the efficacy and safety of a drug. LÄS MER
2. First-pass Intestinal Metabolism of Drugs : Experiences from in vitro, in vivo and simulation studies
Sammanfattning : The bioavailability of a drug can be described as the fraction of an orally administered dose that reaches the systemic circulation and is often limited by first-pass metabolism in the gut and the liver. It is important to have knowledge about these processes since the systemic blood drug concentration is tightly connected to the effect of the drug. LÄS MER
3. Hepatic Disposition of Drugs and the Utility of Mechanistic Modelling and Simulation
Sammanfattning : The elimination of drugs from the body is in many cases performed by the liver. Much could be gained if an accurate prediction of this process could be made early in the development of new drugs. However, for the elimination to occur, the drug molecule needs first to get inside the liver cell. LÄS MER
4. Physiologically Based Pharmacometric Models for Colistin and the Immune Response to Bacterial Infection
Sammanfattning : Antibiotic treatment failure might be due to bacterial resistance or suboptimal exposure at target site and there is a lack of knowledge on the interaction between antimicrobial pharmacodynamics (PD) and the immune response to bacterial infections. Therefore, it is crucial to develop tools to increase the understanding of drug disposition to better evaluate antibiotic candidates in drug development and to elucidate the role of the immune system in bacterial infections. LÄS MER
5. Clinical pharmacokinetic/pharmacodynamic modelling of 5a-reductase inhibitors for the treatment of benign prostatic hyperplasia
Sammanfattning : Dihydrotestosterone (DHT), a potent androgen necessary for the development of benign prostatic hyperplasia (BPH) is formed from testosterone by the enzyme 5α-reductase, of which there are two types. The irreversible 5α-reductase inhibitors dutasteride, which inhibits both isozymes, and finasteride, which inhibits only one, are intended for the treatment of BPH. LÄS MER
